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Introduction
The importance of thyrotropin receptor (TSHR) agonist antibodies in the manifestations of Graves' disease (GD) is recognized. There are, however, no convincing reports of TSHR-specific T cells. We have previously cloned T cells specific for thyroglobulin and thyroid peroxidase (TPO) from GD lymphoid infiltrates and used autologous EBVtransformed B cell lines (EBVL) transfected with an expression vector encoding TPO to efficiently detect TPO-specific T cells. Here we used EBVL transfected with TSHR to seek TSHR-specific T cells in the GD infiltrates, after cloning the in vivo activated T cells without antigen. Graves' disease (GD)' is a common cause of organ-specific autoimmunity in humans. Autoantibodies against three major autoantigens, thyroid peroxidase (TPO), thyroglobulin (Tg) , and the thyroid stimulating hormone (thyrotropin) receptor (TSHR) are detected in serum from the majority of patients with GD and are frequently used to confirm the diagnosis. In the case of the anti-TSHR response, the agonist autoantibodies are pathogenic and responsible for the clinical manifestations of disease, by mimicking the effects of TSH and inducing the overproduction of thyroid hormone (for review see reference 1).
Less is known, however, about the T cell response to these autoantigens. We have previously shown that antigen-specific T cells may be cloned from diseased thyroid tissue and that at least some of these T cells respond to thyroid epithelium, Tg, or TPO (2, 3) . Additional clones were found in the latter study to be unresponsive to TPO or Tg, but proliferated vigorously when exposed to autologous thyroid epithelium (TEC). Progress was hampered by limitations in obtaining sufficient autologous antigen presenting cells (APC) from individual patients for our studies and by nonspecific stimulation or inhibition of proliferation using recombinant autoantigen. These problems led us to consider an alternative approach of presenting the autoantigen: the transfection of cDNA encoding autoantigen into autologous EBV-transformed B cell lines (EBVL) (4) . The capacity of these cells to effectively present TPO to specific T cells (even at low APC/T cell ratios) confirmed that like other cell surface proteins, membrane-bound TPO is internalized and its peptides are recycled with class II molecules (5, 6) . Unfortunately, no TSHR-specific T cells were identified at that time, consistent with the lack of convincing data in the literature. It was unclear, however, whether these findings were due to the absence of TSHR-specific T cells in that patient alone or in Graves' disease per se. The presence of TSHR autoantibodies might be explicable on the basis of "intermolecular help" of TSHR-specific B cells by TPO-specific T cells, since TSHR and TPO are "linked molecules" by virtue of their coexpression on TEC (7) .
The availability of clinical material from additional patients provided us with the opportunity to study the antigen specificity and functional characteristics of additional T cell clones. In this study, autologous EBV-transformed B cell lines from a second patient with active GD at the time of surgery were successfully transfected with expression plasmids encoding the cDNA for full-length human TPO (8) . Surface expression of TSHR was assessed by comparing the binding of highly purified bovine '15I-labeled TSH (RSR, Cardiff, United Kingdom) to EBVL transfected with pREP4-TSHR (EBVL-TSHR) or untransfected EBVL as described previously (4) .
Culture conditions. Thyroid-derived T cell clones were maintained in 10% heat-inactivated HS in RPMI independently of antigen by restimulation every 10-14 d with OKT3, IL-2, and irradiated allogeneic PBM followed by expansion in IL-2-containing medium (2) . At no time were clones or lines exposed to specific antigen, except in proliferation assays. Proliferative responses to transfected and untransfected EBVL were performed after fixation of these cells in 0.05% glutaraldehyde (9) . Unless otherwise indicated, 50,000 EBVL and 20,000 T cells were then dispensed into each triplicate well of round-bottomed 96-well culture plates (Nunc, Kamstrup, Denmark). In some cultures, IL-2 was added at a final concentration of 5 ng/ml after 48 h of incubation.
Background levels of cellular proliferation were assessed by cultures of EBVL Cytokine production by T cell clones. T cell clones were stimulated to release cytokines 12-14 d after the last OKT3 stimulation. After adjusting their concentration to 106/ml, T cells were cultured in 10% HS containing soluble OKT3, 1 lsg/ml, and PMA, 10 ng/ml. 24 h later, supernatants were harvested by centrifugation and stored at -20°C until assayed in specific capture ELISA. Supernatants from all the clones were assayed in parallel on the same day for IFNy (kindly provided by Dr. D. Novick, Weizmann Institute, Rehovot, Israel; clone 3.3 for coating, biotinylated clone 166.5 for detection, using rhIFNy in 10% HS in RPMI as standard), IL-4 (kindly provided by Dr. F. di Padova, Sandoz Pharma AG, Basel, Switzerland; clone 141-1 for coating, biotinylated clone 1-38-10 for detection, and rhIL-4 in 10% HS in RPMI as standard), and IL-10 (kindly provided by Dr. K. Moore and Dr. J. Abrams, DNAX; clone 9D7 for coating, biotinylated clone 12G8 for detection and rhIL-10 diluted in 10% HS in RPMI as standard). The sensitivities of these assays are 120, 40, and 120 pg/ml, respectively. The concentration of IL-2 was estimated using a standard CTLL bioassay with a sensitivity of 200 pg/ml. T (Fig. 2) . Surprisingly, in this individual, no clones (of 30) responded to EBVL-TPO, unlike the results of a previous GD patient studied extensively (3, 4) . The proliferative responses of clones 8.6, 8.18, and 8.21 were specific for EBVL transfected with TSHR. When 20 separate, independent assays were performed, the TSHR responsiveness of these 3 clones was maintained and was reproducible, with an overall mean, median, and range of SI values of 7.5, 4.9, and 3.3-15.1, respectively. Furthermore, there was a clear relationship between the number of EBVL-TSHR present and the proliferative response observed in TSHR-specific (Fig. 3  A) but not irrelevant clones (Fig. 3 B and C) The proliferative responses to EBVL-TSHR were relatively minor compared with those detected by TPO-specific clones from a previous patient with active Graves' disease, CX81 (4). Since it was conceivable that this might be secondary to poor IL-2 release by TSHR-stimulated Th2-like T cells, these clones were restimulated with EBVL in the presence or absence of exogenous IL-2 added at 48 h. Preliminary experiments demonstrated that these conditions were optimal for minimizing the enhancement of background counts. As shown in Fig. 4 , responses to EBVL-TSHR were amplified -10-fold in the presence of IL-2 (and to a lesser extent in the uncloned infiltrate). Responses in previously unresponsive or panresponsive clones, however, were not altered.
Cytokine release by T cell clones. Since secretion of IL-2 by human clones (unlike murine clones) does not always parallel that of IENy (12, 13), T with stimulation (P > 0.13 in all cases), they produced significantly less IFNy than EBVL unresponsive or panresponsive clones from the same thyroid (Table I) (18) or myelin basic protein (19) . Unfortunately, the finding of autoantigen-responsive T cells in the blood of healthy individuals makes it impossible to determine whether the T cells identified are ever activated at the site of disease and involved in its pathogenesis or are simply part of the normal precursor pool and were activated in vitro.
Using an alternative approach that we developed, we have
shown that T cells can be cloned from the active site of disease in autoimmune thyroid disease and that many of these clones respond to tissue-specific autoantigens (3). T cells are first expanded in IL-2 to select for in vivo activated cells, then cloned and maintained in the absence of antigen until screening. In this way, T cell clones responsive to at least three thyroid autoantigens have been identified in a patient with active GD (3) . The response to thyroid antigens in this patient (CX81) was heterogeneous, with clones responsive to Tg, at least three TPOderived epitopes, and a third group of T cells specific for autologous TEC (but neither to purified Tg nor to recombinant TPO) (3). The lack of a preparation of recombinant TSHR prevented us from fully defining the T cell antigen repertoire in patient CX81 at that time. Together with limitations in obtaining sufficient autologous APC for ongoing work, these problems led us to consider an alternative approach to presenting antigen: the transfection of cDNAs encoding TPO or TSHR into autologous EBV-transformed B cell lines (4). When TEC-responsive and -unresponsive clones from patient CX81 were restudied, however, no TSHR-responsive T cells were identified despite the capacity of transfected cells to effectively present the endogenously synthesized TPO antigen to specific T cells (4) . This was surprising, in view of the evidence that the thyroid is the major site of autoantibody (including TSHR autoantibody) production in many patients (20) (21) (22) and is thus a likely source of TSHR-specific T cells and B cells. Therefore, it was unclear whether these findings were best explained by the absence of TSHR-specific T cells in Graves' disease per se, in patient CX81 alone, or at a frequency too low to be detected by nonantigen-stimulated cloning.
The availability of clinical material from additional patients with active disease provided us with an opportunity to identify additional thyroid T cell autoantigens and to characterize the function of the corresponding T cells. By transfecting the EBVL of patient T8 with expression vectors encoding the entire TSHR or TPO, continuous lines of autoantigen presenting cells were generated. Transfected EBVL expressed the transmembrane forms of these antigens, as shown by the binding of anti-TPO mAb and radiolabeled TSH to EBVL-TPO and EBVL-TSHR, respectively (Fig. 1) . The capacity of these cells to effectively present TSHR to three CD4' T cell clones and reproducibly stimulate them confirmed that, like other cell surface proteins, including transfected TPO (4, 5), TSHR is internalized and its peptides are recycled with class II molecules. The responses to EBVL-TSHR by clones 8.6, 8.18, and 8.21 were not due to release of nonspecific growth factors by this cell line. This is because the EBVL were fixed before use in proliferative assays, thus preventing growth factor release, but also a large number of autologous clones derived from the same thyroid failed to be stimulated by EBVL-TSHR (Fig. 3 A) . Furthermore, there was a clear relationship between the number of EBVL-TSHR (but not control EBVL) cells per culture and the proliferative response observed. Finally, there was nothing to distinguish EBVL-TSHR from other lines in terms of class H, ICAM-I, or CD28 ligand expression (data not shown), making it unlikely that the responses seen were a result of nonspecific stimulation by surface molecules. Since the only form of recombinant TSHR available was a nonspecific stimulator of all clones (including those of known irrelevant antigen specificity), confirmatory testing using conventional culture techniques was unfortunately impossible.
It is unclear why the proliferative responses to EBVL-TSHR observed in patient T8, while reproducible, were relatively minor (median SI = 4.9, mean > 7) compared with those obtained with TPO-responsive clones from patient CX81 (median SI = 122) in a previous study (3) . One possible clue to the mechanism of the low responses is provided by the observation that proliferative responses to EBVL-TSHR were specifically enhanced in the presence of exogenous 1L-2, added at a time to minimize an increase in background counts (Fig. 4) . These experiments were prompted by the description of not only murine and human Th2 clones with low IL-2 synthesis (23, 24) , but also of allergen-specific human Th2 cell clones whose proliferative response to antigen was dependent on the addition of exogenous IL-2 or 1L-4 (23, 25) . These results are difficult to reconcile with the capacity of these clones to produce IL-2 when exposed to potent stimuli like OKT3 and PMA (Table  I ). That they may synthesize only small quantities of IL-2 in vivo, or after suboptimal stimulation with fixed EBVL in vitro, cannot be excluded (26) .
These results provide insights into why convincing Th2-like TSHR-responsive T cells may have eluded identification for so long (27, 28). As well as the technical problems described, both the method of cloning and the testing procedures used by ourselves and other groups have probably diminished the likelihood of expanding, cloning, and correctly identifying antigen-specific Th2 clones. In addition to its roles as a B cell growth factor and inducer of Th2 cells in primary antigen responses (29, 30) , 11L-4 is a T cell growth factor and is required by Th2 cells for their successful expansion and long term maintenance in culture (23, 29, 31 (33) .
The initial observation that murine T cells could be classified on the basis of their cytokine production has been confirmed in a number of human studies of patients suffering from infections, allergic disease, or immunodeficiency (for review see reference 34). Human Thl cells produce predominantly IFN-y, 1L-2, and TNF,3 and mediate delayed hypersensitivity responses, whereas Th2 cells produce mainly 1L-4, 1L-5, and 1L-6 and promote the growth and function of B cells. Both subsets may produce IL-10 in humans (12, 13, 25) . T cells with a less polarized profile of cytokine release are classified as ThO and are characteristic of the majority of randomly generated clones in humans. The relationship between these subsets and naive 1L-2-producing pTh cells is unclear, but the best evidence is that these differentiate into one or other types during priming (30, 35, 36) . All Th subsets were observed in this study (Table  I ). In line with previous studies of clones (of unknown antigen specificity) from patients with autoimmune thyroid disease ( 15, 37, 38) , the majority of thyroid-derived clones from patients CX81, T13, and T8 had a clear predominance of IFNy over 11-4 release characteristic of a Thl lymphokine profile. On the other hand, if one restricts analysis to T cells responsive to thyroid autoantigens (in our studies), a different pattern emerges. For example, four of the five TPO-specific clones from patient CX81 displayed a Thl lymphokine profile (the remaining clone was more characteristic of ThO), whereas cytokines released by the three TSHR-responsive clones from patient T8 were more characteristic of ThO or Th2 cells (Table  I) . Indeed, the relatively low IFNy release and high IL-4:IFNy ratios were the only features to distinguish these clones from those of any other group.
The heterogeneity of cytokine release by both TPO-responsive and TSHR-specific T cell clones is of particular interest and has interesting implications for understanding the pathogenesis of GD. The reason for the compartmentalization of three TSHR-responsive clones with a broadly similar cytokine profile is uncertain, but one possible explanation is that they may represent functional Th2 cells which assist the production of pathogenic TSHR autoantibodies. Similarly, one of the TPO-responsive clones (clone 37) produces significant quantities of IL-4. Unlike murine clones, most human Th2 clones secrete a mixture of predominantly IL-4 with some IFN'y and IL-2 as well (4, 13, 15, 25) . Not only are anti-TSHR and anti-TPO antibodies almost entirely IgG, (39, 40) , but little IL-4 is required to promote the synthesis of this subclass in humans and is comparable with the levels observed in these clones (41) . IgG, is also relatively spared from the suppressive effect of IFNy on antibody production, particularly compared with the suppression of IgE synthesis, and even Thl-like clones can promote the synthesis of IgG, (10, 12, 25, 41) . The release of IL-4 and IL-1O by the same T cell provides another way of helping B cell responses, since this combination is synergistic in promoting B cell growth and differentiation ( 16) . The presence of a mixture of Thl and Th2 cells in an antibody-driven disease like GD is not unprecedented. Heterogeneity of cytokine release may even be a prerequisite for the recruitment of additional host cells into the affected tissue, the proliferation of IL-2-dependent but nonproducing Th2 cells, and the induction of antibody synthesis.
Based on the expression of HLA class II antigen by GD TEC, we previously proposed that cytokines such as IFN-y could induce local upregulation of class II expression and antigen presenting capacity resulting in autoantigen presentation within the thyroid (42) perpetuated by mutual restimulation between autoreactive T cells and TEC presenting autoantigens (42, 43) . Since TEC can present influenza peptide to specific T cell clones (44) , restimulate TPO-specific T cells cloned from the same thyroid (2, 3), express cell surface accessory molecules like ICAM-I and LFA-3 (45, 46), and secrete IL-l and IL-6 (47), they have many of the characteristics normally associated with APC, a capacity confirmed by other workers in the field (for example see reference 48). The ability of transfected EBVL, in this and previous studies, to effectively present endogenously synthesized TPO and TSHR supports the concept that cells expressing surface autoantigen (such as TEC) could act as APC, as long as they also possess appropriate costimulatory properties. Since GD thyroid contains dendritic cells, it is also conceivable that the primary autoimmune response could be initiated either by professional APC presenting locally liberated antigen or by TEC assisted by third party "bystander" APC delivering the necessary costimuli (26) . Suboptimal activation of naive T cells by TEC might lead not to complete T cell inactivation or deletion but to alteration of the Thl /Th2 balance in their antigen-specific response (26, 49) .
Despite the absence of a clear understanding of the initiating events, it is evident that the thyroid microenvironment contains all of the components required for an ongoing autoimmune response; class II-expressing TEC capable of restimulating T cells, other APC, autoreactive T cell clones able to release IFN'y upon stimulation with processed TPO or TSHR, and other clones which proliferate poorly to TSHR but secrete IL-4 and IL-10 thus promoting the synthesis of pathogenic autoantibodies. Ongoing work using modified culture and screening techniques should facilitate the identification of additional TSHRresponsive clones and should help define the functional characteristics and the range of autoantigenic epitopes recognized.
These analyses may eventually permit the development of antigen-specific immunotherapy.
